Vertex Appoints Lloyd Carney to its Board of Directors
BOSTON--(BUSINESS WIRE)--Feb 21, 2019--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Lloyd Carney has been appointed to its board of directors as an independent director. Mr. Carney is a prominent technology executive with experience leading innovative, high-growth organizations. He currently serves as the Chairman and Chief Executive Officer of ChaSerg Technology Acquisition Corp., a technology acquisition company. The addition of Mr. Carney brings Vertex’s board of directors to 10 members.
“We are thrilled to have Lloyd join the Vertex Board. His wealth of leadership and management experience paired with his passion for technology and innovation bring an invaluable perspective to the Vertex leadership team,” said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex.
“It’s an honor to join an organization with a strong track record of discovering new medicines to treat life-threatening diseases like cystic fibrosis,” said Lloyd Carney. “I look forward to working with my fellow board members to support Vertex in its continued efforts to serially innovate for the benefit of people with serious diseases.”
Prior to his role at ChaSerg, Mr. Carney served as Chief Executive Officer of Brocade Communications Systems, a global supplier of networking hardware and software, until its acquisition by Broadcom in 2017. Previously, Mr. Carney served as Chief Executive Officer of Xsigo Systems, a cloud-based infrastructure solutions provider, until its acquisition by Oracle. He has also served as the Chief Executive Officer and Chairman of Micromuse Inc., a software solutions provider for business and service assurance. Earlier in his career he held senior leadership roles at Juniper Networks Inc., Nortel Networks Inc., and Bay Networks Inc. Mr. Carney currently serves as an independent director of Visa Inc. and the chairman of the board of Nuance Communications Inc.
Mr. Carney holds a Bachelor of Science degree in electrical engineering technology from Wentworth Institute, a Master of Science degree in applied business management from Lesley College, and an honorary doctorate degree in engineering from Wentworth Institute.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Founded in 1989 in Cambridge, Mass., Vertex’s headquarters is now located in Boston’s Innovation District. Today, the company has research and development sites and commercial offices in the United States, Europe, Canada, Australia and Latin America. Vertex is consistently recognized as one of the industry’s top places to work, including being named to Science magazine’s Top Employers in the life sciences ranking for nine years in a row.
For additional information and the latest updates from the company, please visit www.vrtx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190221005847/en/
CONTACT: Vertex Pharmaceuticals Incorporated
Michael Partridge, 617-341-6108
Eric Rojas, 617-961-7205
Zach Barber, 617-341-6470
North America: +1 617-341-6992
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Vertex Pharmaceuticals Incorporated
Copyright Business Wire 2019.
PUB: 02/21/2019 04:01 PM/DISC: 02/21/2019 04:01 PM